The ASPIRE trial, recently published in the NEJM, examined the role of aspirin after patients with VTE’s had completed at least 6 weeks of full anticoagulation (although most completed 6+ months). This is the sister trial to the WARFASA trial, which required 6-18 months of warfarin therapy.